The Alpha 1 Antitrypsin pipeline drugs market research report outlays comprehensive information on the Alpha 1 Antitrypsin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Alpha 1 Antitrypsin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Genetic Disorders, Respiratory, Immunology, and Gastrointestinal which include the indications Alpha-1 Antitrypsin Deficiency (A1AD), Charcot-Marie-Tooth Disease, Emphysema, Bronchiectasis, Graft Versus Host Disease (GVHD), Lung Transplant Rejection, Liver Diseases, and Eosinophilic Esophagitis. It also reviews key players involved in Alpha 1 Antitrypsin targeted therapeutics development with respective active and dormant or discontinued products.
The Alpha 1 Antitrypsin pipeline targets constitutes close to 32 molecules. Out of which, approximately 32 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 3, 1, 1, 16, and 4 respectively.
Alpha 1 Antitrypsin overview
Alpha-1 antitrypsin (AAT) is a protein produced in the liver that helps protect the lungs from damage caused by inflammation. An inhibitor of serine proteases, its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. It irreversibly inhibits trypsin, chymotrypsin, and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time, and has proteolytic activity against insulin and plasmin.
For a complete picture of Alpha 1 Antitrypsin’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
